PPCB logo

PPCB
Propanc Biopharma Inc

1,292
Mkt Cap
$3.94M
Volume
19,591.00
52W High
$270.25
52W Low
$1.56
PE Ratio
-0.05
PPCB Fundamentals
Price
$1.75
Prev Close
$1.73
Open
$1.70
50D MA
$2.62
Beta
0.00
Avg. Volume
269,938.12
EPS (Annual)
-$371.22
P/B
0.15
Rev/Employee
$0.00
$18.38
Loading...
Loading...
News
all
press releases
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation PPCB
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Propanc Biopharma Inc. (NASDAQ: PPCB) resulting from allegations that Propanc may have issued materially misleading business information to the investing...
News Placeholder
More News
News Placeholder
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
News Placeholder
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
News Placeholder
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology
Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors’ attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity’s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...
News Placeholder
Why Propanc stock Is Tumbling In Premarket Today
The biotech firm announced a $4 million share sale alongside its Nasdaq uplisting, sending trading volumes surging to record levels.
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available